“We use cookies on this website to enhance your user experience and to personalise content. By clicking any link or continuing to use our Website you agree to our cookies as per our Privacy Policy. Read More” Ok, I agree

Ziprasidone Hydrochloride (Ziprasidone Hydrochloride)

Trade Name : ziprasidone hydrochloride

NorthStar Rx LLC

CAPSULE

Strength 20 mg/1

ZIPRASIDONE HYDROCHLORIDE Atypical Antipsychotic [EPC]

Delivery Process

Submit a Request

You can fill in a request for your medicine through the form provided. You can access the form by clicking on the ‘Get Price’ button.

We’ll Get in Touch

Once we review your request, we’ll send you an estimated price for the medicine within 2-5 days.

Confirmation and Payment

You can fill in a request for your medicine through the form provided. You can access the form by clicking on the ‘Get Price’ button.

Submit a Request

You can fill in a request for your medicine through the form provided. You can access the form by clicking on the ‘Get Price’ button.

Product information is meant for

Wholesalers Suppliers Exporters Doctors MOH Tender Supplies Hospitals Brand CROs Comparator Supplies Generic Cooperate Sourcing Individual Patients Indian Institutional Buyers

Disclaimer

Trade Marks displayed in compliance with provisions of: Trademark Act, 1999 u/s 30 and 30 (1) of "Fair use"

GNH India is WHO GDP and ISO 9001 2015 Certified Pharmaceutical Wholesaler/ Supplier/ Exporters/ Importer from India of Ziprasidone Hydrochloride (Ziprasidone Hydrochloride) which is also known as ziprasidone hydrochloride and Manufactured by NorthStar Rx LLC. It is available in strength of 20 mg/1 per ml. Read more

Ziprasidone Hydrochloride (Ziprasidone Hydrochloride) is supplied for Tenders/ Emergency imports/ Un - licensed, Specials, Orphan drug/ Name patient line/ RLD supplies/ Reference listed drugs/ Comparator Drug/ Bio-Similar/ Innovator samples For Clinical trials.  Click to know price.     Read less

Packaging and Delivery

Validated Cold Chain Shipment

We deliver your medicines through a validated cold chain shipment process. This process is used as these medicines need to manufactured, transported and stored at very specific temperatures, utilizing thermal and refrigerated packaging methods.

Inquire directly from our website and get 5% off on any medicine!

We deliver your medicines through a validated cold chain shipment process. This process is used as these medicines need to manufactured, transported and stored at very specific temperatures, utilizing thermal and refrigerated packaging methods.

Read more

About GNH

We deliver your medicines through a validated cold chain shipment process. This process is used as these medicines need to manufactured, transported and stored at very specific temperatures, utilizing thermal and refrigerated packaging methods.

We deliver your medicines through a validated cold chain shipment process. This process is used as these medicines need to manufactured, transported and stored at very specific temperatures, utilizing thermal and refrigerated packaging methods.

Read more
  • No data
  • Arrayn- Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. Ziprasidone is not approved for the treatment of patients with dementia-related psychosis [see Warnings and Precautions n- Arrayn- ]).
  • See full prescribing information for complete boxed warning.
  • Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of deathn- Array
  • Ziprasidone is not approved for the treatment of patients with dementia-related psychosisn- Array
  • Ziprasidone hydrochloride capsules are indicated for the treatment of schizophrenia, as monotherapy for the acute treatment of bipolar manic or mixed episodes, and as an adjunct to lithium or valproate for the maintenance treatment of bipolar disorder. When deciding among the alternative treatments available for the condition needing treatment, the prescriber should consider the finding of ziprasidoneu2019s greater capacity to prolong the QT/QTc interval compared to several other antipsychotic drugs [seeu00a0]. Prolongation of the QTc interval is associated in some other drugs with the ability to cause torsade de pointes-type arrhythmia, a potentially fatal polymorphic ventricular tachycardia, and sudden death. In many cases this would lead to the conclusion that other drugs should be tried first. Whether ziprasidone will cause torsade de pointes or increase the rate of sudden death is not yet known [see ]
  • Schizophrenia
  • Bipolar I Disorder (Acute Mixed or Manic Episodes and Maintenance Treatment as an Adjunct to Lithium or Valproate)
  • Ziprasidone hydrochloride capsule is an atypical antipsychotic. In choosing among treatments, prescribers should be aware of the capacity of ziprasidone hydrochloride capsule to prolong the QT interval and may consider the use of other drugs first n
  • Ziprasidone hydrochloride capsule is indicated as an oral formulation for the:
  • u2022 Treatment of schizophrenia. ()
  • u2022 Acute treatment as monotherapy of manic or mixed episodes associated with bipolar I disorder. ()
  • u2022 Maintenance treatment of bipolar I disorder as an adjunct to lithium or valproate. ()
  • Give oral doses with food.
  • Schizophrenia: Initiate at 20 mg twice daily. Daily dosage may be adjusted up to 80 mg twice daily. Dose adjustments should occur at intervals of not less than 2 days. Safety and efficacy has been demonstrated in doses up to 100 mg twice daily. The lowest effective dose should be used. n
  • Acute treatment of manic/mixed episodes of bipolar I disorder: Initiate at 40 mg twice daily. Increase to 60 mg or 80 mg twice daily on day 2 of treatment. Subsequent dose adjustments should be based on tolerability and efficacy within the range of 40 to 80 mg twice daily. n
  • Maintenance treatment of bipolar I disorder as an adjunct to lithium or valproate: Continue treatment at the same dose on which the patient was initially stabilized, within the range of 40 to 80 mg twice daily. u00a0
  • Ziprasidone hydrochloride capsules, 20 mg (ziprasidone), are light pink to brown granular powder filled in size u201c4u201d hard gelatin capsules having Lavender opaque cap and Flesh opaque body, imprinted u201cRDYu201d on cap and u201c256u201d on body with black ink.u00a0u00a0
  • Ziprasidone hydrochloride capsules, 40 mg (ziprasidone), are light pink to brown granular powder filled in size u201c4u201d hard gelatin capsules having Lavender opaque cap and LT Turquoise blue opaque body, imprinted u201cRDYu201d on cap and u201c257u201d on body with black ink.u00a0
  • Ziprasidone hydrochloride capsules, 60 mg (ziprasidone), are light pink to brown granular powder filled in size u201c3u201d hard gelatin capsules having Flesh opaque cap and Flesh opaque body, imprinted u201cRDYu201d on cap and u201c258u201d on body with black ink.u00a0
  • Ziprasidone hydrochloride capsules, 80 mg (ziprasidone), are light pink to brown granular powder filled in size u201c2u201d hard gelatin capsules having LT Turquoise blue opaque cap and Flesh opaque body, imprinted u201cRDYu201d on cap and u201c259u201d on body with black ink.
  • Capsules: 20 mg, 40 mg, 60 mg, and 80 mg n
  • No data
  • Do not use in patients with a known history of QT prolongation n
  • Do not use in patients with recent acute myocardial infarction n
  • Do not use in patients with uncompensated heart failure n
  • Do not use in combination with other drugs that have demonstrated QT prolongation n
  • Do not use in patients with known hypersensitivity to ziprasidone n
  • No data
  • Cerebrovascular Adverse Reactions in Elderly Patients with Dementia-Related Psychosis:
  • QT Interval Prolongation
  • Neuroleptic Malignant Syndrome (NMS)
  • Severe Cutaneous Adverse Reactions, sun- .
  • Tardive Dyskinesia
  • Metabolic Changes
  • Hyperglycemia and Diabetes Mellitus (DM)
  • Dyslipidemia
  • Weight Gain
  • Rash
  • Orthostatic Hypotension
  • Leukopenia, Neutropenia, and Agranulocytosis
  • Seizures
  • Potential for Cognitive and Motor impairment
  • Suicide
  • Commonly observed adverse reactions (incidence u22655% and at least twice the incidence for placebo) weren
  • u2022 Schizophrenia: Somnolence, respiratory tract infection. n
  • u2022 Manic and Mixed Episodes Associated with Bipolar Disorder: Somnolence, extrapyramidal symptoms, dizziness, akathisia, abnormal vision, asthenia, vomiting u00a0
  • To report SUSPECTED ADVERSE REACTIONS, contact NorthStar Rx LLC at 1-844-375-6847 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
  • Drug-drug interactions can be pharmacodynamic (combined pharmacologic effects) or pharmacokinetic (alteration of plasma levels). The risks of using ziprasidone in combination with other drugs have been evaluated as described below. All interactions studies have been conducted with oral ziprasidone. Based upon the pharmacodynamic and pharmacokinetic profile of ziprasidone, possible interactions could be anticipated:
  • Ziprasidone should not be used in combination with other drugs that have demonstrated QT prolongation. (, )
  • The absorption of ziprasidone is increased up to two-fold in the presence of food. n
  • The full prescribing information contains additional drug interactions. .
  • No data
  • Pregnancy:
  • Pediatric Use:
  • Ziprasidone has not been systematically studied, in animals or humans, for its potential for abuse, tolerance, or physical dependence. While the clinical trials did not reveal any tendency for drug-seeking behavior, these observations were not systematic and it is not possible to predict on the basis of this limited experience the extent to which ziprasidone will be misused, diverted, and/or abused once marketed. Consequently, patients should be evaluated carefully for a history of drug abuse, and such patients should be observed closely for signs of ziprasidone misuse or abuse (e.g., development of tolerance, increases in dose, drug-seeking behavior).
  • No data
  • Ziprasidone hydrochloride, USP is an atypical antipsychotic available as capsules for oral administration. Ziprasidone is a psychotropic agent that is chemically unrelated to phenothiazine or butyrophenone antipsychotic agents. It has a molecular weight of 412.94 (free base), with the following chemical name: 5-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-6-chloro-1,3-dihydro-2H-indol-2-one. The molecular formula of CHClNOS (free base of ziprasidone) represents the following structural formula:
  • Ziprasidone hydrochloride capsules contain a hydrochloride salt of ziprasidone. Chemically, ziprasidone hydrochloride USP is 5-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-6-chloro-1,3-dihydro-2H-indol-2-one, hydrochloride. The molecular formula is CHClNOS u00b7 HCl and its molecular weight is 449.40. Ziprasidone hydrochloride, USP is a light pink to pink colored powder.
  • Ziprasidone hydrochloride capsules are supplied for oral administration in 20 mg, 40 mg, 60 mg, and 80 mg capsules. Ziprasidone hydrochloride capsules contain ziprasidone hydrochloride, anhydrous lactose, magnesium stearate, polysorbate 80, povidone (PVK-30), pregelatinized starch and silicon dioxide. The components of the capsule shells are FD&C Blue #1, FD&C Red #3, gelatin, red iron oxide and titanium dioxide.
  • The capsule shells are imprinted with black ink. The components of black ink (Black SW-9008/SW-9009) are black iron oxide, butyl alcohol, dehydrated alcohol, isopropyl alcohol, potassium hydroxide, propylene glycol, shellac and strong ammonia solution.
  • No data
  • Carcinogenesis
  • Lifetime carcinogenicity studies were conducted with ziprasidone in Long Evans rats and CD-1 mice. Ziprasidone was administered for 24 months in the diet at doses of 2, 6, or 12 mg/kg/day to rats, and 50, 100, or 200 mg/kg/day to mice (0.1 to 0.6 and 1 to 5 times the maximum recommended human dose (MRHD) of 200 mg/day based on mg/mbody surface area, respectively). In the rat study, there was no evidence of an increased incidence of tumors compared to controls. In male mice, there was no increase in incidence of tumors relative to controls. In female mice, there were dose-related increases in the incidences of pituitary gland adenoma and carcinoma, and mammary gland adenocarcinoma at all doses tested (50 to 200 mg/kg/day or 1 to 5 times the MRHD based on mg/mbody surface area). Proliferative changes in the pituitary and mammary glands of rodents have been observed following chronic administration of other antipsychotic agents and are considered to be prolactin-mediated. Increases in serum prolactin were observed in a 1-month dietary study in female, but not male, mice at 100 and 200 mg/kg/day (or 2.5 and 5 times the MRHD based on mg/mbody surface area). Ziprasidone had no effect on serum prolactin in rats in a 5-week dietary study at the doses that were used in the carcinogenicity study. The relevance for human risk of the findings of prolactin-mediated endocrine tumors in rodents is unknown [see n .
  • Mutagenesis
  • Ziprasidone was tested in the Ames bacterial mutation assay, the in vitro mammalian cell gene mutation mouse lymphoma assay, the in vitro chromosomal aberration assay in human lymphocytes, and the in vivo chromosomal aberration assay in mouse bone marrow. There was a reproducible mutagenic response in the Ames assay in one strain of S. typhimurium in the absence of metabolic activation. Positive results were obtained in both the in vitro mammalian cell gene mutation assay and the in vitro chromosomal aberration assay in human lymphocytes.
  • Impairment of Fertility
  • Ziprasidone was shown to increase time to copulation in Sprague-Dawley rats in two fertility and early embryonic development studies at doses of 10 to 160 mg/kg/day (0.5 to 8 times the MRHD of 200 mg/day based on mg/mbody surface area). Fertility rate was reduced at 160 mg/kg/day (8 times the MRHD based on mg/mbody surface area). There was no effect on fertility at 40 mg/kg/day (2 times the MRHD based on mg/mbody surface area). The effect on fertility appeared to be in the female since fertility was not impaired when males given 160 mg/kg/day (8 times the MRHD based on mg/mbody surface area) were mated with untreated females.
  • No data
  • Ziprasidone hydrochloride capsules, 20 mg (ziprasidone), are light pink to brown granular powder filled in size u201c4u201d hard gelatin capsules having Lavender opaque cap and Flesh opaque body, imprinted u201cRDYu201d on cap and u201c256u201d on body with black ink, and are supplied in bottles of 60u2019s.
  • Bottles of 60 u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0 NDC 16714-835-01
  • Ziprasidone hydrochloride capsules, 40 mg (ziprasidone), are light pink to brown granular powder filled in size u201c4u201d hard gelatin capsules having Lavender opaque cap and LT Turquoise blue opaque body, imprinted u201cRDYu201d on cap and u201c257u201d on body with black ink, and are supplied in bottles of 60u2019s.
  • Bottles of 60 u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0 NDC 16714-836-01
  • Ziprasidone hydrochloride capsules, 60 mg (ziprasidone), are light pink to brown granular powder filled in size u201c3u201d hard gelatin capsules having Flesh opaque cap and Flesh opaque body, imprinted u201cRDYu201d on cap and u201c258u201d on body with black ink, and are supplied in bottles of 60u2019s.
  • Bottles of 60 u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0 NDC 16714-837-01
  • Ziprasidone hydrochloride capsules, 80 mg (ziprasidone), are light pink to brown granular powder filled in size u201c2u201d hard gelatin capsules having LT Turquoise blue opaque cap and Flesh opaque body, imprinted u201cRDYu201d on cap and u201c259u201d on body with black ink, and are supplied in bottles of 60u2019s.
  • Bottles of 60 u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0 NDC 16714-838-01
  • Ziprasidone hydrochloride capsules should be stored at 20u00b0 to 25u00b0C (68u00b0 to 77u00b0F);excursions permitted to 15u00b0 to 30u00b0C(59u00b0 to 86u00b0F) [See USP Controlled Room Temperature].
  • Advise the patient to read the FDA-approved patient labeling (Patient Information).
  • Adn- ministration with Food
  • Instruct patients to take ziprasidone hydrochloride capsules with food for optimal absorption. The absorption of ziprasidone is increased up to two-fold in the presence of food [see ].
  • QTn- c Prolongation
  • Advise patients to inform their health care providers of the following: History of QT prolongation; recent acute myocardial infarction; uncompensated heart failure; prescription of other drugs that have demonstrated QT prolongation; risk for significant electrolyte abnormalities; and history of cardiac arrhythmia [seeu00a0].
  • Instruct patients to report the onset of any conditions that put them at risk for significant electrolyte disturbances, hypokalemia in particular, including but not limited to the initiation of diuretic therapy or prolonged diarrhea. In addition, instruct patients to report symptoms such as dizziness, palpitations, or syncope to the prescriber [seeu00a0].
  • Sen- vere Cutaneous Adverse Reactions n- Warnings and Precautions n
  • Pregnancy
  • Advise pregnant women to notify their healthcare provider if they become pregnant or intend to become pregnant during treatment with ziprasidone hydrochloride capsules. Advise patients that ziprasidone hydrochloride capsules may cause extrapyramidal and/or withdrawal symptoms (agitation, hypertonia, hypotonia, tremor, somnolence, respiratory distress, and feeding disorder) in a neonate. Advise patients that there is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to ziprasidone hydrochloride capsules during pregnancy [see ].
  • Lactation
  • Advise breastfeeding women using ziprasidone hydrochloride capsules to monitor infants for excess sedation, irritability, poor feeding, and extrapyramidal symptoms (tremors, and abnormal muscle movements) and to seek medical care if they notice these signs [see ].
  • Infertility
  • Advise females of reproductive potential that ziprasidone hydrochloride capsules may impair fertility due to an increase in serum prolactin levels. The effects on fertility are reversible [see and ].
  • Ziprasidone Hydrochloride Capsules
  • (zi pras' i done hye'' droe klor' ide)
  • Information for patients taking ziprasidone hydrochloride capsules or their caregivers
  • This summary contains important information about ziprasidone hydrochloride capsules. It is not meant to take the place of your doctoru2019s instructions. Read this information carefully before you take ziprasidone hydrochloride capsules. Ask your doctor or pharmacist if you do not understand any of this information or if you want to know more about ziprasidone hydrochloride capsules. u00a0
  • What are ziprasidone n- hydrochloride capsules?
  • Arrayn- u00a0
  • Who should take ziprasidone n- hydrochloride capsules?
  • Only your doctor can know if ziprasidone hydrochloride capsules are right for you. Ziprasidone hydrochloride capsules may be prescribed for you if you have schizophrenia or bipolar disorder. Symptoms of schizophrenia may include:
  • Symptoms of manic or mixed episodes of bipolar disorder may include:
  • u2022 extremely high or irritable mood
  • u2022 increased energy, activity, and restlessness
  • u2022 racing thoughts or talking very fast
  • u2022 easily distracted
  • u2022 little need for sleep
  • If you show a response to ziprasidone hydrochloride capsules, your symptoms may improve. If you continue to take ziprasidone hydrochloride capsules there is less chance of your symptoms returning. Do not stop taking the capsules even when you feel better without first discussing it with your doctor.
  • It is also important to remember that ziprasidone hydrochloride capsules should be taken with food.
  • What is the most important safety information I should know about ziprasidone hydrochloride capsules?
  • Ziprasidone hydrochloride capsules are not approved for the treatment of patients with dementia-related psychosis. Elderly patients with a diagnosis of psychosis related to dementia treated with antipsychotics are at an increased risk of death when compared to patients who are treated with placebo (a sugar pill).
  • Ziprasidone hydrochloride capsules are an effective drug to treat the symptoms of schizophrenia and the manic or mixed episodes of bipolar disorder. However, one potential side effect is that it may change the way the electrical current in your heart works more than some other drugs. The change is small and it is not known whether this will be harmful, but some other drugs that cause this kind of change have in rare cases caused dangerous heart rhythm abnormalitiesBecause of this, ziprasidone hydrochloride capsules should be used only after your doctor has considered this risk for ziprasidone hydrochloride capsules against the risks and benefits of other medications available for treating schizophrenia or bipolar manic and mixed episodes.
  • Your risk of dangerous changes in heart rhythm can be increased if you are taking certain other medicines and if you already have certain abnormal heart conditions. Therefore, it is important to tell your doctor about any other medicines that you take, including non-prescription medicines, supplements, and herbal medicines. You must also tell your doctor about any heart problems you have or have had.
  • Who should NOT take ziprasidone n- hydrochloride capsules?
  • Elderly patients with a diagnosis of psychosis related to dementia. Ziprasidone hydrochloride capsules are not approved for the treatment of these patients.
  • Anything that can increase the chance of a heart rhythm abnormality should be avoided. Therefore, do not take ziprasidone hydrochloride capsules if: You have certain heart diseases, for example, long QT syndrome, a recent heart attack, severe heart failure, or certain irregularities of heart rhythm (discuss the specifics with your doctor) You are currently taking medications that should not be taken in combination with ziprasidone, for example, dofetilide, sotalol, quinidine, other Class Ia and III anti-arrhythmics, mesoridazine, thioridazine, chlorpromazine, droperidol, pimozide, sparfloxacin, gatifloxacin, moxifloxacin, halofantrine, mefloquine, pentamidine, arsenic trioxide, levomethadyl acetate, dolasetron mesylate, probucol or tacrolimus.
  • What to tell your doctor before you start ziprasidone hydrochloride capsules?
  • Only your doctor can decide if ziprasidone hydrochloride capsules are right for you. Before you start ziprasidone hydrochloride capsules, be sure to tell your doctor if you:
  • Your doctor may want you to get additional laboratory tests to see if ziprasidone hydrochloride capsules are an appropriate treatment for you.
  • Ziprasidone hydrochloride capsules and other medicines
  • There are some medications that may be unsafe to use when taking ziprasidone hydrochloride capsules, and there are some medicines that can affect how well ziprasidone hydrochloride capsules works. While you are on ziprasidone hydrochloride capsules, check with your doctor before starting any new prescription or over-the-counter medications, including natural/herbal remedies.
  • How to take ziprasidone hydrochloride capsules
  • u2022 Take ziprasidone hydrochloride capsules only as directed by your doctor.
  • u2022 Swallow the capsules whole.
  • u2022 Take ziprasidone hydrochloride capsules with food.
  • u2022 It is best to take ziprasidone hydrochloride capsules at the same time each day.
  • u2022 Ziprasidone hydrochloride capsules may take a few weeks to work. It is important to be patient.
  • u2022 Do not change your dose or stop taking your medicine without your doctoru2019s approval.
  • u2022 Remember to keep taking your capsules, even when you feel better.
  • Possible side effects
  • Because these problems could mean youu2019re having a heart rhythm abnormality, contact your doctor if you:
  • Common side effects of ziprasidone hydrochloride capsules include the following and should also be discussed with your doctor if they occur:
  • If you develop any side effects that concern you, talk with your doctor. It is particularly important to tell your doctor if you have diarrhea, vomiting, or another illness that can cause you to lose fluids. Your doctor may want to check your blood to make sure that you have the right amount of important salts after such illnesses.
  • For a list of all side effects that have been reported, ask your doctor or pharmacist for the ziprasidone hydrochloride capsules Professional Package Insert.
  • What to do for an overdose
  • In case of an overdose, call your doctor or poison control center right away or go to the nearest emergency room.
  • Other Important Safety Information
  • A serious condition called neuroleptic malignant syndrome (NMS) can occur with all antipsychotic medications including ziprasidone hydrochloride capsules. Signs of NMS include very high fever, rigid muscles, shaking, confusion, sweating, or increased heart rate and blood pressure. NMS is a rare but serious side effect that could be fatal. Therefore, tell your doctor if you experience any of these signs.
  • Delayed-onset drug reaction called drug reaction with eosinophilia and systemic symptoms (DRESS) can occur with ziprasidone. Signs of DRESS may include rash, fever, and swollen lymph nodes. Other severe cutaneous adverse reactions (SCAR), such as Stevens-Johnson syndrome can occur with ziprasidone. Signs of Stevens-Johnson syndrome may include rash with blisters which could include ulcers in mouth, skin shedding, fever and target-like spots in the skin. DRESS and other SCAR are sometimes fatal; therefore, tell your doctor immediately if you experience any of these signs.u00a0
  • Adverse reactions related to high blood sugar (hyperglycemia), sometimes serious, have been reported in patients treated with atypical antipsychotics. There have been few reports of hyperglycemia or diabetes in patients treated with ziprasidone hydrochloride capsules, and it is not known if ziprasidone hydrochloride capsules are associated with these reactions. Patients treated with an atypical antipsychotic should be monitored for symptoms of hyperglycemia.
  • Dizziness caused by a drop in your blood pressure may occur with ziprasidone hydrochloride capsules, especially when you first start taking this medication or when the dose is increased. If this happens, be careful not to stand up too quickly, and talk to your doctor about the problem.
  • Before taking ziprasidone hydrochloride capsules, tell your doctor if you
  • Because ziprasidone hydrochloride capsules can cause sleepiness, be careful when operating machinery or driving a motor vehicle.
  • Since medications of the same drug class as ziprasidone hydrochloride capsules may interfere with the ability of the body to adjust to heat, it is best to avoid situations involving high temperature or humidity.
  • It is best to avoid consuming alcoholic beverages while taking ziprasidone hydrochloride capsules. Call your doctor if you take more than the amount of ziprasidone hydrochloride capsules prescribed by your doctor. Ziprasidone hydrochloride capsules have not been shown to be safe or effective in the treatment of children and teenagers under the age of 18 years old.
  • Keep ziprasidone hydrochloride capsules and all medicines out of the reach of children.
  • How to store ziprasidone hydrochloride capsules
  • Store ziprasidone hydrochloride capsules at room temperature 20u00b0 to 25u00b0C (68u00b0 to 77u00b0F); excursions permitted to 15u00b0 to 30u00b0C (59u00b0 to 86u00b0F).
  • For more information about n- ziprasidone hydrochloride capsules
  • This sheet is only a summary. Ziprasidone hydrochloride capsules are a prescription medicine and only your doctor can decide if it is right for you. If you have any questions or want more information about ziprasidone hydrochloride capsules, talk with your doctor or pharmacist or call, 1-844-375-6847.
  • Rx Only
  • Manufactured for:
  • NorthStar Rx LLCMemphis, TN 38141
  • Manufactured by:
  • Dr. Reddy's Laboratories Limited
  • Bachupally - 500 090 INDIA.
  • Revised: 2/2020
  • Ziprasidone Hydrochloride Capsules, 20 mg - Container Label
  • Ziprasidone Hydrochloride Capsules, 40 mg - Container Label
  • Ziprasidone Hydrochloride Capsules, 60 mg - Container Label
  • Ziprasidone Hydrochloride Capsules, 80 mg - Container Label

Similar Products

Desogestrel And Ethinyl Estradiol (Emoquette)

Desogestrel And Ethinyl Estradiol (Emoquette)

Manufacturer: REMEDYREPACK INC.

Presentation: KIT

Strength:

Pack Size:

Diphenoxylate Hydrochloride And Atropine Sulfate (Diphenoxylate Hydrochloride And Atropine Sulfate)

Diphenoxylate Hydrochloride And Atropine Sulfate (Diphenoxylate Hydrochloride And Atropine Sulfate)

Manufacturer: REMEDYREPACK INC.

Presentation: TABLET

Strength: 2.5; .025 mg/1; mg/1

Pack Size:

Fluoxetine Hydrochloride (Fluoxetine)

Fluoxetine Hydrochloride (Fluoxetine)

Manufacturer: REMEDYREPACK INC.

Presentation: CAPSULE

Strength: 40 mg/1

Pack Size:

Metoprolol Succinate (Metoprolol Succinate)

Metoprolol Succinate (Metoprolol Succinate)

Manufacturer: REMEDYREPACK INC.

Presentation: TABLET, EXTENDED RELEASE

Strength: 25 mg/1

Pack Size:

Losartan Potassium (Losartan Potassium)

Losartan Potassium (Losartan Potassium)

Manufacturer: REMEDYREPACK INC.

Presentation: TABLET, FILM COATED

Strength: 25 mg/1

Pack Size:

Browse Our Services And Processes

Comparator Sourcing for Clinical Trials

Comparator Sourcing for Clinical Trials

GNH India brings over 10 years of experience in Comparator

Read More

Name Patient Supply

Name Patient Supply

Today, the exact cause for many rare diseases remains unknown

Read More

Validated Cold Chain Shipment

Validated Cold Chain Shipment

With shifting of pharma industry from synthetic molecules to biologic

Read More

Clinical Trials Supply

Clinical Trials Supply

STOP SOURCING..... START SMART SOURCING...... COME STRAIGHT TO THE SOURCE

Read More

Pharmaceutical Contract Manufacturing

Pharmaceutical Contract Manufacturing

GNH Provides Contract Manufacturing services for: Generic Medicines with following

Read More

Pricing

Pricing

PRICING POLICY Terms of sales are typically prepaid, unless otherwise

Read More

Disclaimer

Please see the Legal Notice for detailed terms and disclaimers. The Legal Notice governs the use of this Website and by accessing and using this Website you agree to be bound by and accept the Legal Notice.

Browse from other international pharmaceuticals

General

64020 Products

GNH India Brings to over 64036 Product SKUs from India all at 1 place with easy access and global deliveries.

US NDC

71245 Products

GNH India Brings to over 71252 Product SKUs from India all at 1 place with easy access and global deliveries.

Canadian DIN

51046 Products

GNH India Brings to over 51047 Product SKUs from India all at 1 place with easy access and global deliveries.

Swiss Drugs

150 Products

GNH India Brings to over 150 Product SKUs from India all at 1 place with easy access and global deliveries.

NZ Drugs

13296 Products

GNH Brings to over 13298 Product SKUs from India all at 1 place with easy access and global deliveries.

FAQ

Check out our delivery process

Can’t find what
you’re looking for?

Contact US
Get Price

Are you an existing customer or a vendor of GNH India? Log in here to

View your Transaction
COMPANY
SERVICES
QUICK LINKS
CONTACT US
Registered Office Address:

Unit # G- 14, 15, 16, 17, Ground Floor, Prabhadevi Industrial Estate, Enterprises Industrial Premises, 408, Veer Sawarkar Road, Prabhadevi,
Mumbai 400025 India

US Office Address:

GNH Pharmaceuticals USA LLC,
Suite E # 499, 1235 EAST BLVD,
Charlotte, NC, 28203, U.S.A
TEL: +1 704 557 0412

Pharmexcil
DB
FIEO-2016
SiteLock

Copyright © 2024 GNHIndia .com. All Rights Reserved. Please read Legal Notice for further details.

Disclaimer: Product names, logos, brands and other trademarks featured or referred to are the property of their respective trademark holders.